Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 1/2022

01-02-2022 | SARS-CoV-2 | The Global Epidemic (S Vermund, Section Editor)

HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development

Authors: Brittany Ober Shepherd, David Chang, Sandhya Vasan, Julie Ake, Kayvon Modjarrad

Published in: Current HIV/AIDS Reports | Issue 1/2022

Login to get access

Abstract

Purpose of Review

This review examines the major advances and obstacles in the field of HIV vaccine research as they pertain to informing the development of vaccines against SARS-CoV-2.

Recent Findings

Although the field of HIV research has yet to deliver a licensed vaccine, the technologies developed and knowledge gained in basic scientific disciplines, translational research, and community engagement have positively impacted the development of vaccines for other viruses, most notably and recently for SARS-CoV-2. These advances include the advent of viral vectors and mRNA as vaccine delivery platforms; the use of structural biology for immunogen design; an emergence of novel adjuvant formulations; a more sophisticated understanding of viral phylogenetics; improvements in the development and harmonization of accurate assays for vaccine immunogenicity; and maturation of the fields of bioethics and community engagement for clinical trials conducted in diverse populations.

Summary

Decades of foundational research and investments into HIV biology, though yet to yield an authorized or approved vaccine for HIV/AIDS, have now paid dividends in the rapid development of safe and effective SARS-CoV-2 vaccines. This latter success presents an opportunity for feedback on improved pathways for development of safe and efficacious vaccines against HIV and other pathogens.
Literature
1.
Wolff JA, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465–8.PubMedCrossRef
2.
Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–80.PubMedCrossRef
3.
Coughlan L, et al. Heterologous two-dose vaccination with Simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults. EBioMedicine. 2018;29:146–54.PubMedPubMedCentralCrossRef
4.
Dicks MD, et al., A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One, 2012. 7(7): e40385.
5.
Barouch DH, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13–19). Lancet. 2018;392(10143):232–43.PubMedPubMedCentralCrossRef
6.
Sadoff J, et al., Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. New England Journal of Medicine, 2021.
7.
Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020;396(10249):467–78.CrossRef
8.
9.
Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.PubMedCrossRef
10.
Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384(5):403–16.PubMedCrossRef
11.
Gaschen B, et al. Diversity considerations in HIV-1 vaccine selection. Science. 2002;296(5577):2354–60.PubMedCrossRef
12.
13.
14.
Kwong PD, What are the most powerful immunogen design vaccine strategies? A structural biologist's perspective. Cold Spring Harb Perspect Biol, 2017. 9(11).
15.
Ward AB, Wilson IA. Innovations in structure-based antigen design and immune monitoring for next generation vaccines. Curr Opin Immunol. 2020;65:50–6.PubMedPubMedCentralCrossRef
16.
Liu H, et al. The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. Protein Cell. 2018;9(7):596–615.PubMedPubMedCentralCrossRef
17.
18.
Julien JP, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013;342(6165):1477–83.PubMedCrossRef
19.
20.
21.
Sanders RW, et al., HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 2015. 349(6244): p. aac4223.
22.
23.
24.
25.
Stewart-Jones GB, et al., A cysteine zipper stabilizes a pre-fusion f glycoprotein vaccine for respiratory syncytial virus. PLoS One, 2015. 10(6): e0128779.
26.
27.
Krarup A, et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun. 2015;6:8143.PubMedCrossRef
28.
29.
Pitisuttithum P, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok Thailand. J Infect Dis. 2006;194(12):1661–71.PubMedCrossRef
30.
Rerks-Ngarm S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–20.PubMedCrossRef
31.
O’Connell RJ, et al. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. J Infect Dis. 2016;213(12):1946–54.PubMedPubMedCentralCrossRef
32.
Weissburg RP, et al. Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Pharm Res. 1995;12(10):1439–46.PubMedCrossRef
33.
Flynn NM, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5):654–65.PubMedCrossRef
34.
Pegu P, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol. 2013;87(3):1708–19.PubMedPubMedCentralCrossRef
35.
Tuero I, et al., Mucosal B cells are associated with delayed SIV acquisition in vaccinated female but not male rhesus macaques following SIVmac251 rectal challenge. PLoS Pathog, 2015. 11(8): e1005101.
36.
Fouts TR, et al. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci U S A. 2015;112(9):E992–9.PubMedPubMedCentralCrossRef
37.
Iyer SS, et al. Codelivery of envelope protein in alum with MVA vaccine induces CXCR3-Biased CXCR5+ and CXCR5- CD4 T Cell Responses in Rhesus Macaques. J Immunol. 2015;195(3):994–1005.PubMedCrossRef
38.
39.
Apostólico Jde S, et al., HIV envelope trimer specific immune response is influenced by different adjuvant formulations and heterologous prime-boost. PLoS One, 2016. 11(1): e0145637.
40.
Leroux-Roels I, et al. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine. 2010;28(43):7016–24.PubMedCrossRef
41.
Alving CR, et al. Liposomal adjuvants for human vaccines. Expert Opin Drug Deliv. 2016;13(6):807–16.PubMedCrossRef
42.
Beck Z, Matyas GR, Alving CR. Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. Biochim Biophys Acta. 2015;1848(3):775–80.PubMedCrossRef
43.
Beck Z, et al. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine. 2015;33(42):5578–87.PubMedCrossRef
44.
Wieczorek L, et al. Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research. J Virol. 2015;89(15):7478–93.PubMedPubMedCentralCrossRef
45.
46.
Robb ML, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis. 2012;12(7):531–7.PubMedPubMedCentralCrossRef
47.
Zolla-Pazner S, et al., Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One, 2013. 8(1): p. e53629.
48.
Rerks-Ngarm S, et al. Randomized, double-blind evaluation of late boost strategies for HIV-Uninfected vaccine recipients in the RV144 HIV vaccine efficacy trial. J Infect Dis. 2017;215(8):1255–63.PubMedPubMedCentralCrossRef
49.
Easterhoff D, et al., Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog, 2017. 13(2): p. e1006182.
50.
Easterhoff D, et al. Boosting with AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity breadth and potency. J Virol, 2020. 94(4).
51.
Easterhoff D, et al. HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. JCI Insight, 2020. 5(2).
52.
Atmar RL, et al. Heterologous SARS-CoV-2 booster vaccinations - preliminary report. medRxiv, 2021.
53.
Montefiori D, et al. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med, 2007. 4(12): e348.
54.
Polonis VR, et al. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology. 2008;375(2):315–20.PubMedCrossRef
55.
Joyce MG, et al. Efficacy of a broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine in nonhuman primates. bioRxiv, 2021: p. 2021.03.24.436523.
56.
Weissman D, et al. D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host Microbe. 2021;29(1):23-31.e4.PubMedCrossRef
57.
Sholukh AM, et al. Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials. medRxiv, 2020.
58.
59.
Gilbert PB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2021: p. eab3435.
60.
Khoury DS, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11.PubMedCrossRef
61.
Dearlove B, et al. A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. Proc Natl Acad Sci U S A. 2020;117(38):23652–62.PubMedPubMedCentralCrossRef
62.
Wu K, et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. bioRxiv, 2021: p. 2021.04.13.439482.
63.
64.
65.
Webb Hooper M, Nápoles AM, Pérez-Stable EJ, COVID-19 and racial/ethnic disparities. JAMA, 2020. 323(24): p. 2466–2467.
66.
Weintraub RL, et al. COVID-19 vaccine to vaccination: why leaders must invest in delivery strategies now. Health Aff (Millwood). 2021;40(1):33–41.CrossRef
67.
Katz IT, et al. From vaccine nationalism to vaccine equity - finding a path forward. N Engl J Med. 2021;384(14):1281–3.PubMedCrossRef
68.
69.
Killen J, Harrington M, Fauci AS. MSM, AIDS research activism, and HAART. Lancet. 2012;380(9839):314–6.PubMedCrossRef
70.
71.
72.
73.
Metadata
Title
HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development
Authors
Brittany Ober Shepherd
David Chang
Sandhya Vasan
Julie Ake
Kayvon Modjarrad
Publication date
01-02-2022
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 1/2022
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-021-00597-4

Other articles of this Issue 1/2022

Current HIV/AIDS Reports 1/2022 Go to the issue

The Global Epidemic (S Vermund, Section Editor)

COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa

Central Nervous System and Cognition (SS Spudich, Section Editor)

Emerging Single-cell Approaches to Understand HIV in the Central Nervous System

Central Nervous System and Cognition (SS Spudich, Section Editor)

Central Nervous System Impact of Perinatally Acquired HIV in Adolescents and Adults: an Update

The Global Epidemic (S Vermund, Section Editor)

HIV and COVID-19 in Latin America and the Caribbean

The Global Epidemic (S Vermund, Section Editor)

Socioeconomic Burdens of the COVID-19 Pandemic on LMIC Populations with Increased HIV Vulnerabilities

HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

The Reproductive Transition: Effects on Viral Replication, Immune Activation, and Metabolism in Women with HIV infection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits